The IIAR is a member of the UICC
Anticancer Research
Anticancer Research is an international print and online monthly journal designed to rapidly publish peer-reviewed original works and reviews on all aspects of experimental and clinical cancer research.
Established: 1981
Impact factor (2021): 2.480
Current issue contents >>
In Vivo
In Vivo is an international online and open-access journal designed to bring together peer-reviewed original works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management.
Established: 1987
Impact factor (2021): 2.155
Current issue contents >>
Cancer Genomics & Proteomics
Cancer Genomics & Proteomics is an international peer-reviewed online and open-access journal designed to rapidly publish high quality articles and reviews on the application of genomic and proteomic technology to experimental and clinical cancer research.
Established: 2004
Impact factor (2021): 4.069
Current issue contents >>
Cancer Diagnosis & Prognosis
Cancer Diagnosis & Prognosis is an international online open-access peer-reviewed journal, designed to rapidly publish original and review papers on experimental and clinical research advancing the knowledge on the diagnosis and prognosis of all types of cancer, leukemia and metastasis.
Established: 2021
CALL FOR PAPERS
Special Issue of Anticancer Research on NEW ANTICANCER AGENTS
Topics:
A. Experimental studies on “Νew Anticancer Agents”
1. Synthesis and evaluation in vitro and in vivo
2. Mechanism of action
3. Reversal of resistance to anticancer agents
4. Oncolytic viruses
B. Clinical studies on “New Anticancer Agents”
1. Pharmacology
2. Clinical trials
3. Combination chemotherapy
4. Immunotherapeutic agents
5. New methodologies in drug delivery
6. Vaccines
Publication date: March 2, 2023
Submission deadline: December 30, 2022
Instructions for the preparation and submission of reviews and original articles.
CALL FOR PAPERS
Special Issue of Anticancer Research on PROSTATE CANCER
Topics:
- New diagnostic procedures
- Genetic polymorphisms
- Environmental and dietary risk factors
- Chemoprevention
- Treatment of early prostate cancer
- Treatment of metastatic prostate cancer
- Advances in surgical procedures
- New drugs and drug combinations
- Radiotherapy
- Immunotherapy
- Benign prostate hyperplasia
The aim of this special issue is to cover all aspects of the current advances in the experimental and clinical research on prostate cancer.
Publication date: January 5, 2023
Submission deadline: October 30, 2022
Instructions for the preparation and submission of reviews and original articles.
Anticancer Research, In Vivo, Cancer Genomics & Proteomics, and Cancer Diagnosis & Prognosis are independent international journals, published by the International Institute of Anticancer Research (IIAR), and have had no relation or association with other publishers since their establishment.
At the IIAR, we are committed to maintaining the highest content quality and the most rapid processing of submitted articles to our four journals.
All submitted articles are peer-reviewed to secure a valid assessment. Our preliminary review includes a detailed assessment of the suitability and validity of the conclusions of all cited references.
We value the support of our policy by our Authors and Readers and we look forward to receiving comments and suggestions for the
continuous improvement of our services.
Now you can access the entire contents of the IIAR journals published from 2013 till today
with ease on your Android© or iOS phone or tablet with our newly designed app, freely available on Google Play Store and App Store
Articles in ANTICANCER RESEARCH are fully available to everyone as open access 2 years after publication.
IN VIVO (from January 2017) and CANCER GENOMICS & PROTEOMICS (from January 2013) are published online-only with open access.
Should you come across any errors in this website, please inform: admin@iiar-anticancer.org